Pharmacogenetic variants and risk of remdesivir‐associated liver enzyme elevations in Million Veteran Program participants hospitalized with COVID‐19

Remdesivir is the first US Food and Drug Administration (FDA)‐approved drug for the treatment of coronavirus disease 2019 (COVID‐19). We conducted a retrospective pharmacogenetic study to examine remdesivir‐associated liver enzyme elevation among Million Veteran Program participants hospitalized wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuteja, Sony, Yu, Zhihong, Wilson, Otis, Chen, Hua‐Chang, Wendt, Frank, Chung, Cecilia P., Shah, Shailja C., Hunt, Christine M., Suzuki, Ayako, Chanfreau, Catherine, Gorman, Bryan R., Joseph, Jacob, Luoh, Shiuh‐Wen, Napolioni, Valerio, Robinson‐Cohen, Cassianne, Tao, Ran, Zhou, Jin, Chang, Kyong‐Mi, Hung, Adriana M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347806/
https://www.ncbi.nlm.nih.gov/pubmed/35684976
http://dx.doi.org/10.1111/cts.13313

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9347806/
https://www.ncbi.nlm.nih.gov/pubmed/35684976
http://dx.doi.org/10.1111/cts.13313

Ejemplares similares